Biodesix AI Stock Analysis
Want to see BDSX full AI Analyst Report?
Biodesix (BDSX) AI Stock Analysis
Biodesix
(NASDAQ:BDSX)
BDSX scores low primarily due to weak financial fundamentals: high leverage versus equity, ongoing losses, and continued cash burn. Technicals add further downside pressure, with the stock trading well below key moving averages and extremely weak momentum readings. The earnings call provides the main offset, supported by reiterated growth and high-margin guidance plus improving profitability metrics, but execution risks (salesforce ramp, development services timing, and cash dependence) remain significant.
Biodesix Key Performance Indicators (KPIs)
Revenue by SegmentShows how much revenue each business unit or product line generates, highlighting areas of strength and potential growth within the company’s portfolio.
Diagnostic testing is the clear growth engine—volume-driven expansion plus modest ASP gains are lifting top-line momentum and gross margins, supporting the raised 2026 guide; primary‑care adoption and a bigger salesforce make that ramp look repeatable. Development services are becoming a meaningful, backlog-backed second leg but remain timing‑sensitive and add quarter-to-quarter volatility. Execution risk (sales productivity, logistics, collections) and limited cash mean converting this momentum into sustained profitability is the key investor watchpoint.
The FlyBiodesix (BDSX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $82.38M
- Dividend Yield
- ―
- Average Volume (3M)
- 155.05K
- Price to Earnings (P/E)
- -3.7
- Beta (1Y)
- 0.65
- Revenue Growth
- 31.23%
- EPS Growth
- 48.56%
- Country
- US
- Employees
- 334
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Biodesix Business Overview & Revenue Model
Company Description
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL...
How the Company Makes Money
Biodesix makes money primarily by performing and selling its proprietary diagnostic tests as clinical laboratory services and recognizing revenue per test delivered. In practice, this is largely a fee-for-service model in which Biodesix bills for tes...
Biodesix Earnings Call Summary
The call had a mixed but overall positive tone. Biodesix reported solid year-over-year revenue, diagnostic testing volume, margin and adjusted EBITDA improvements, continued clinical validation, expanding health system integrations and progress in digital diagnostics and MRD programs. These positives were tempered by results falling short of expectations, reduced sales capacity, primary care seasonality, lower development services revenue, a 6% decline in average revenue per test and a modest normalized fourth-quarter growth outlook. Management characterized the main issues as execution and timing challenges rather than changes in demand or market opportunity.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Biodesix now expects total revenue of $101 million to $103 million, with the midpoint representing approximately 15% growth over 2025, gross margins of approximately 80% and continued progress towards profitability; for the fourth quarter, it is anticipating around $1 million for development services and a step-up in lung diagnostic revenues over third quarter. For 2027, development services revenue is expected to be probably in the 7% to 8% of total revenue range, with a depending on the year average between 7% and 10%, and 7% to 8% is a good target for the year; the company has approximately 110 sales representatives in the field, plans to exit the year with approximately 115 representatives, and expects a hiring cadence of approximately 6 to 8 on a quarterly basis, also stated as 6% to 8%.
Biodesix Financial Statement Overview
Summary
Financial performance is weak overall despite strong revenue momentum. The income statement shows rapid TTM revenue growth (+220.8%) and solid gross margin (~64%), but the company remains meaningfully loss-making (TTM net margin ~-25.7%). The balance sheet is the largest risk: ~$72.4M debt versus ~$8.7M equity indicates high leverage and a thin cushion. Cash flow is also pressured with negative TTM operating cash flow (~-$18.2M) and negative free cash flow (~-$19.1M), implying continued reliance on external funding until profitability improves.
Income Statement
38NegativeBalance Sheet
24NegativeCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 105.21M | 88.50M | 71.32M | 49.09M | 38.21M | 54.51M |
| Gross Profit | 67.27M | 71.78M | 55.75M | 36.08M | 24.06M | 23.99M |
| EBITDA | -15.14M | -21.95M | -29.22M | -37.10M | -51.53M | -35.47M |
| Net Income | -27.08M | -35.27M | -42.93M | -52.15M | -65.45M | -43.16M |
Balance Sheet | ||||||
| Total Assets | 93.94M | 87.48M | 97.24M | 99.10M | 92.91M | 76.10M |
| Cash, Cash Equivalents and Short-Term Investments | 28.41M | 18.99M | 26.25M | 26.28M | 43.09M | 32.71M |
| Total Debt | 72.44M | 72.85M | 61.98M | 60.69M | 31.85M | 10.01M |
| Total Liabilities | 85.27M | 89.94M | 76.37M | 94.52M | 72.30M | 56.37M |
| Stockholders Equity | 8.68M | -2.46M | 20.88M | 4.58M | 20.61M | 19.73M |
Cash Flow | ||||||
| Free Cash Flow | -19.09M | -23.67M | -51.88M | -45.93M | -48.51M | -30.77M |
| Operating Cash Flow | -18.16M | -23.27M | -48.65M | -22.87M | -44.97M | -28.22M |
| Investing Cash Flow | -1.10M | -403.00K | -3.44M | -23.06M | -3.53M | -2.55M |
| Financing Cash Flow | 31.06M | 16.42M | 52.05M | 29.13M | 58.88M | 1.26M |
Biodesix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDSX, the sentiment is Negative. The current price of 10.12 is below the 20-day moving average (MA) of 20.10, below the 50-day MA of 24.57, and below the 200-day MA of 18.89, indicating a bearish trend. The MACD of -3.78 indicates Positive momentum. The RSI at 24.25 is Positive, neither overbought nor oversold. The STOCH value of 14.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDSX.
Biodesix Risk Analysis
Biodesix disclosed 83 risk factors in its most recent earnings report. Biodesix reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBiodesix Peers Comparison
Overall Rating
PRPO56Neutral
SERA54Neutral
BNR52Neutral
VNRX45Neutral- BDSX43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PRPO | 56Neutral | $42.34M | -41.02 | -7.84% | ― | 21.76% | 22.97% |
| SERA | 54Neutral | $79.14M | -2.90 | -52.54% | ― | 1.05% | 13.67% |
| BNR | 52Neutral | $133.27M | -1.37 | -12.97% | ― | -3.65% | 51.30% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| VNRX | 45Neutral | $5.15M | -0.05 | 77.10% | ― | 86.32% | 21.31% |
| BDSX | 43Neutral | $111.11M | -3.67 | -442.34% | ― | 31.23% | 48.56% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BDSX | Biodesix, Inc. | 10.12 | 2.22 | 28.10% | |
| VNRX | VolitionRX Ltd. | 0.20 | -6.89 | -97.14% | |
| PRPO | Precipio | 24.80 | 5.28 | 27.05% | |
| BNR | Burning Rock Biotech Ltd. | 13.24 | 1.92 | 16.96% | |
| SERA | Sera Prognostics, Inc. | 1.94 | -1.01 | -34.24% |
Biodesix Corporate Events
Biodesix Announces Departure of Chief Commercial Officer
NeutralOn November 2, 2026, Biodesix, Inc. agreed that the employment of Chief Commercial Officer Kieran O’Kane would end effective that day. O’Kane was eligible for separation benefits under his existing Executive Severance and Change in Control Agreement...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026